GW Pharma's Guy sells to Whittle
A round-up of the biggest director buys today so far.
Geoffrey Guy, executive chairman of GW Pharmaceuticals, has sold almost £600,000 of shares in the cannabis-based medicine firm to co-founder Brian Whittle.
The purchase of 750,000 shares from Guy at 79p each cost Whittle, who retired as a director at GW last year, £592,500.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Guy also gifted, for nil consideration, a further 782,111 shares to Whittle and members of Whittle's family.
Despite transferring over 1.5m shares, or 1.3% of the business, Guy still owns a 15.2% stake.
GW posted a maiden annual profit last month. It made £4m on revenue up to £16.1m from £5.7m thanks to increased sales and milestone revenue from Almirall and Sativax
Top Director Buys
Value: £129,366
Value: £53,480
Value: £35,340
Value: £24,878
Value: £24,878
Value: £22,825
Value: £19,902
Value: £11,750
Value: £11,600
Value: £10,536
Top Director Sells
Value: £592,500
-
Revealed: The 10 UK locations which could see the biggest house price growth in 2026Scotland leads the way for house price growth in 2026 according to Zoopla, but what regions will do the best in 2026?
-
Could pensions inheritance tax rule change create liquidity crisis for Sippholders?Pension inheritance tax rule changes from April 2027 could create a liquidity crisis for some self-invested personal pensions (Sipps) holding commercial property. We reveal what you can do to mitigate the impact.
